POINT

Treatment tested

• Ponesimod

  Sphingosine 1-phosphate receptor Edg-1 agonist

Placebo or sham

• Placebo

Other measures (4)

Inclusion Criteria: * Signed informed consent prior to initiation of any study-mandated procedure. * Women of childbearing potential must have a negative pregnancy test and use reliable methods of contraception * Presenting with a diagnosis of MS as defined by the revised (2010) McDonald Diagnostic Criteria for MS with relapsing course from onset (i.e., relapsing-remitting multiple sclerosis (RRMS), or secondary progressive multiple sclerosis (SPMS) with superimposed relapses). * Ongoing treatment with DMF for at least 6 months prior to screening * Active disease after at least 3 months of DMF treatment * Ambulatory and with an EDSS score between 0 and 6.0 (inclusive). Exclusion Criteria: * Lactating or pregnant women and women intending to become pregnant during the study. * Presenting with a diagnosis of MS with progressive course from onset (i.e., primary progressive MS or progressive relapsing MS). * Evidence of a relapse of MS with onset within 30 days prior to baseline EDSS assessment. * Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

This clinical study compares the efficacy, safety, and tolerability of therapy with ponesimod vs placebo in subjects with active RMS who are treated with DMF (Tecfidera®).